The SIAH1–HIPK2–p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death (original) (raw)

Profile image of Bernd KainaBernd Kaina

2019, Molecular Cancer Research

visibility

description

14 pages

link

1 file

Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells

Ana-Maria Florea

Journal of Neurochemistry, 2012

View PDFchevron_right

MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma

Johan Kros

The New England Journal of Medicine, 2005

View PDFchevron_right

Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas

Francesca Garello

Neoplasia, 2017

View PDFchevron_right

Protracted Adjuvant Temozolomide in Glioblastoma Multiforme

Dina Salem

Journal of Cancer Therapy, 2015

View PDFchevron_right

Extended-schedule dose-dense temozolomide in refractory gliomas

Miguel Angel Garcia Gil

Journal of Neuro-Oncology, 2009

View PDFchevron_right

Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level

Jessian Munoz

Oncotarget, 2015

View PDFchevron_right

Glioma Cell Biology

Aleksi Šedo

2014

View PDFchevron_right

Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways

Cf Fung

Neuro-Oncology, 2013

View PDFchevron_right

Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study

Jannick Brennum

Molecular Oncology, 2021

View PDFchevron_right

Glioblastoma: Therapeutic challenges, what lies ahead

Luciana Romão

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2012

View PDFchevron_right

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

Temozolamide-Associated Pancytopenia in a Patient with Glioblastoma Multiforme

Kübra BOZKURT

International Journal of Case Reports, 2019

View PDFchevron_right

KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment

Davide Ragozzino

Oncotarget, 2016

View PDFchevron_right

Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?

Bernd Kaina

International Journal of Molecular Sciences

View PDFchevron_right

Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma

Ting-Chao Chou

Cancer Gene Therapy, 2001

View PDFchevron_right

Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma

Giacomo Signorino

Oncotarget, 2017

View PDFchevron_right

Randomized Study of Postoperative Radiotherapy and Simultaneous Temozolomide without Adjuvant Chemotherapy for Glioblastoma

Peter Frommolt

Strahlentherapie und Onkologie, 2008

View PDFchevron_right

Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth

Jarkko Rautio

Molecular Cancer Therapeutics, 2014

View PDFchevron_right

The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells

nicola perrotti

Journal of Experimental & Clinical Cancer Research

View PDFchevron_right

Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of Mitochondrial Electron Transport Chain

Susan Nozell

Journal of Biological Chemistry, 2010

View PDFchevron_right

Multifaceted Resistance of Gliomas to Temozolomide1

Demetrius Kokkinakis

2002

View PDFchevron_right

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

Martin Van Den Bent

Cancer, 2008

View PDFchevron_right

Multifaceted resistance of gliomas to temozolomide

Demetrius Kokkinakis

Clinical cancer …, 2002

View PDFchevron_right

Combination hyperbaric oxygen and temozolomide therapy in c6 rat glioma model

AKIN SAVAŞ TOKLU

Acta Cirurgica …, 2012

View PDFchevron_right

Targeting c-IAP1, c-IAP2, and Bcl-2 Eliminates Senescent Glioblastoma Cells Following Temozolomide Treatment

Bernd Kaina

Cancers, 2021

View PDFchevron_right

Role of Inflammation and Oxidative Stress Mediators in Gliomas

M'Hammed Aguennouz

Cancers, 2010

View PDFchevron_right

Epigenomic perturbation of novelEGFRenhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide

Itzel Nissen

bioRxiv (Cold Spring Harbor Laboratory), 2023

View PDFchevron_right

Cancer- related protein profile of patient-derived and commercial glioblastoma cell lines exposed to Temozolomide

Anna Bielecka-Wajdman

View PDFchevron_right

Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment

Iwona Wertel

International Journal of Molecular Sciences

View PDFchevron_right

Effect of temozolomide on the U-118 glioma cell line

Helena Carvalheiro

Oncology Letters, 2011

View PDFchevron_right

Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review)

Oleg Kit

International Journal of Oncology

View PDFchevron_right

The Effect of Silibinin in Enhancing Toxicity of Temozolomide and Etoposide in p53 and PTEN-mutated Resistant Glioma Cell Lines

Karam Soliman

Anticancer research, 2015

View PDFchevron_right

BiologyMedicineMolecular Biology Cancer